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We have previously documented the inhibitory activity of RNA aptamers to the RNA-dependent
RNA polymerase of foot-and-mouth disease virus (3Dpol). Here we report their modification and
use with a subgenomic replicon incorporating GFP (pGFP-PAC replicon), allowing replication to
be monitored and quantified in real-time. GFP expression in transfected BHK-21 cells reached a
maximum at approximately 8 h post-transfection, at which time change in morphology of the cells
was consistent with a virus-induced cytopathic effect. However, transfection of replicon-bearing
cells with a 3Dpol aptamer RNA resulted in inhibition of GFP expression and maintenance of
normal cell morphology, whereas a control aptamer RNA had little effect. The inhibition was
correlated with a reduction in 3Dpol (detected by immunoblotting) and shown to be dose
dependent. The 3Dpol aptamers appeared to be more effective than 29-C-methylcytidine
(29CMC). Aptamers to components of the replication complex are therefore useful molecular tools
for studying viral replication and also have potential as diagnostic molecules in the future.
INTRODUCTION
Foot-and-mouth disease is an acute, systemic vesicular
disease in cloven-hoofed animals resulting from infection
by foot-and-mouth disease virus, FMDV (reviewed by
Jamal & Belsham, 2013). Major outbreaks in Taiwan (in
1997) and the UK (in 2001) had serious consequences for
agriculture and tourism (Thompson et al., 2002; Yang et al.,
1999), with losses to the UK estimated in excess of £8 billion.
The disease remains endemic in many parts of Asia, South
America, Africa and the Middle East, including countries
bordering on Europe, such as Turkey. Although severe trade
restrictions are imposed on countries where the disease is
endemic, outbreaks do occur elsewhere. The problem with
controlling the spread of the disease is mainly due to high
infectivity and transmissibility of the virus, and is compli-
cated by the ability of the virus to develop an asymptomatic
carrier state.
Like other picornaviruses, the FMDV genome is a positive-
stranded RNA molecule comprising a large single ORF
flanked by a long 59 untranslated region (UTR), a short
39UTR and a poly(A) tail. The 59UTR contains at least five
domains, including an internal ribosomal entry site (IRES),
which enables cap-independent translation of the viral
proteins (Belsham & Brangwyn, 1990), a poly(C) tract of
unknown function and a cre (cis-acting replication
element), involved in the initiation of RNA replication.
The ORF comprises four major regions (Lpro, P1, P2 and
P3) and is translated into a single polyprotein, which then
undergoes processing. Lpro is the protease responsible for
cleavage of eIF4G and so inhibiting host protein synthesis.
The P1 region encodes the four structural proteins required
for the formation of the capsid. The P2 and P3 regions
encode non-structural proteins responsible for modifica-
tion of the host cell and assembling the replication
machinery. Among these, the RNA-dependent-RNA poly-
merase (RdRp) 3Dpol, its precursor 3CD and the primer
fragment 3B (also known as VPg) are known to be key
proteins in viral RNA replication, although further
precursor proteins are also likely to be involved. There
are several crystal structures of 3Dpol, including a structure
with the 3B protein primer fragment (Ferrer-Orta et al.,
2004, 2006, 2009). The presence of three encoded 3Bs
(Nayak et al., 2005) and the error-prone nature of FMDV
3Dpol (Domingo et al., 2002) are thought to contribute to
the ability of the virus to establish states of fast replication
but also carrier states with reduced replication.
Much of our knowledge about picornaviral replication
comes from studies with poliovirus (PV). However, there
are several interesting differences between PV and FMDV,
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including the presence of three tandem copies of 3B (VPg)
in the FMDV genome and the size and complexity of the
59UTR. FMDV has a very fast replication rate (Domingo &
Holland, 1997; Alexandersen et al., 2002) and it is likely
that some of these unusual properties of the genome are
responsible for this phenotype. Because of the economic
importance and highly infectious nature of FMDV, work
with the virus is restricted to high containment facilities;
however, subgenomic replicons can be safely used to study
many aspects of virus replication. The pGFP-PAC replicon
employed here was modified from the pT7Rep construct
(McInerney et al., 2000), a cDNA of FMDV O1K strain in
which Lpro and most of the structural proteins had been
replaced with a chloramphenicol acetyltransferase gene. This
new construct encodes the full Lpro protein and fragments of
the 1A and 1D proteins flanking a GFP puromycin N-
acetlytransferase (GFP/PAC) reporter gene cassette, which
allows replication to bemonitored in real time (Tulloch et al.,
2014).
We have previously selected and characterized RNA
aptamers that can inhibit 3Dpol activity in vitro
(Ellingham et al., 2006; Bentham et al., 2012). RNA
aptamers are isolated by systematic evolution of ligands by
exponential enrichment (SELEX) and bind their target
molecules with high affinity and specificity. Modification
of the aptamers by inclusion of 29F pyrimidines, for
example, increases stability (Yazbeck et al., 2002; Osborne
& Ellington, 1997). Without modifications to the sugar–
phosphate backbone, the half-life of RNA molecules is
minutes, making both experimental application and
evaluation of therapeutic potential impossible. Several
modifications have therefore been incorporated into
aptamers undergoing clinical trials and in the development
of Macugen, an anti-VEGF (anti-vascular endothelial
growth factor) aptamer, the first commercially available
aptamer therapeutic (Green et al., 1995; Ruckman et al.,
1998; Ng et al., 2006). Furthermore, fluorophores can be
added to the 39 or 59 end of the molecule to facilitate
detection in cells.
We report here the use of chemically modified (29F Cy3)
3Dpol RNA aptamers as tools to investigate replication of
the pGFP-PAC replicon. We showed that the modified
aptamers remained able to inhibit 3Dpol in vitro and
demonstrated (by live cell imaging and immunoblotting)
their ability to effectively inhibit replication.
RESULTS
Modified aptamers inhibit 3Dpol in vitro
Previously, we characterized RNA aptamers selected to
FMDV 3Dpol that were able to inhibit the activity of the
enzyme in vitro (Ellingham et al., 2006). Themost promising
of the aptamers were termed 47 and 52. These shared 75%
similarity in the random, selected region and were also active
when truncated to eliminate the primer binding regions
(termed 47tr and 52tr).We went on to show that 3Dpol could
form RNA–protein fibrils in vitro (the products of an
elongation assay) and that 47tr was able to inhibit their
formation (Bentham et al., 2012). These aptamers were
selected without chemical modification and were therefore
very susceptible to degradation both in serum and in cells.
The incorporation of modified nucleotides into RNAs has
been shown to increase stability; however, such modifica-
tions can alter RNA conformation. One of the least bulky
substituents is fluorine at the 29 position of ribose. In
order to evaluate if the 3Dpol aptamers would tolerate
such modifications and retain inhibitory activity we
resynthesized the aptamers, incorporating 29F and
100
80
60
40
20P
er
ce
nt
ag
e 
of
 fu
ll 
ac
tiv
ity
 o
f 3
D
po
l
120
0
504030
Time (min)
20100 60
3Dpol
3Dpol + 52tr
3Dpol + 2′F-Cy3-52tr
3Dpol + 2′F-Cy3-47tr
3Dpol + 47tr
No 3Dpol
D388A
Fig. 1. Effect of aptamers on the in vitro elongation activity of 3Dpol by incorporation of [32P] UTP. The 3Dpol active site mutant
D388A was included as a negative control. The effects of pre-incubation with 29-fluoro- and Cy3-modified aptamers (29F-Cy3-
47tr and 29F-Cy3-52tr) and unmodified aptamers 47tr and 52tr (4 mM, 20 min) are also shown. Data are mean±SE of three
experiments. Statistical analyses comparing the effects of each aptamer to 3D alone were conducted using a t-test (P,0.01).
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Fig. 2. Aptamers can be detected in BHK-21 cells. (a) Cells grown on glass coverslips were transfected with 50 nM 29F-Cy3-
47tr or 29F-Cy3-52tr aptamer (red). At 24 h post-transfection, cells were fixed, stained (DAPI) and imaged using an upright
confocal microscope (Zeiss). Bars, 10 mm. (b, c) Cells were seeded and maintained for up to 24 h in 10% FCS/DMEM at
37 6C, 5% CO2 prior to transfection with 1 mg pGFP-PAC replicon RNA in the presence or absence of 29F-Cy3-47tr (b) or
29F-Cy3-52tr (c) at final concentrations of 500 nM. An IncuCyte was used to take nine images of every well, every 30 min. A
selection of images at t52, 4, 8 and 12 h post-transfection are shown, as a merge of fluorescent and phase-contrast images,
with mock-treated cells as a control.
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59Cy3, and performed elongation assays, monitoring
[32P]UTP incorporation with a poly(A) template and
oligo(dT) primer. The 3Dpol was able to incorporate
radiolabelled UTP over time under these conditions and
both the unmodified (47tr and 52tr) and modified (29F-
Cy3-47tr and 29F-Cy3-52tr) aptamers were inhibitory
(P,0.01), as shown in Fig. 1. The 3Dpol active site mutant
(D388A) was included as a negative control.
Localization of aptamers in BHK-21 cells
To confirm that the modified aptamers could be delivered
into mammalian cells, samples of both 29F-Cy3-47tr and
29F-Cy3-52tr were transfected into BHK-21 cells. Cells
were stained with DAPI, and the presence of the Cy3
fluorophore allowed direct visualization of the RNA.
Aptamers were detected throughout the cytoplasm but
concentrated in the perinuclear region, for reasons
currently unknown, as shown in Fig. 2(a).
GFP expression as a measure of replication in the
presence and absence of RNA aptamers
The inclusion of a GFP-PAC reporter protein within the
pGFP-PAC replicon allows for the detection of replication
over time using an IncuCyte FLR (Tulloch et al., 2014). In
cells transfected with replicon RNA, GFP expression could
be detected within 4 h, with cytopathic effects becoming
evident, as shown in Fig. 2(b, c) and the supplementary
movies (available in the online Supplementary Material).
However, in cells transfectedwith 29F-Cy3-47tr and 29F-Cy3-
52tr aptamers, inhibition of expression was correlated with
the loss of cytopathic effects, with the cells continuing to grow
normally for the remainder of the experiment (Fig. 2b, c).
In addition to direct visualization, it was also possible to
quantify levels of GFP expression over time using the
approach above. These data confirmed that expression of
GFP reached a maximum after 6–8 h (Fig. 3a and
supplementary movies). Inclusion of 29F-Cy3-47tr or 29F-
Cy3-52tr (500 nM) resulted in a dramatic reduction in
GFP expression, whereas the control aptamer (cRNA,
selected to the unrelated protein, IL-17A) had little effect
(Fig. 3a). The relatively small reduction in GFP expression
could be the result of co-transfection. It was further
demonstrated that the effects of the 29F-Cy3-47tr and 29F-
Cy3-52tr aptamers were dose dependent (Fig. 3b, c),
with almost total inhibition of GFP expression at 125 nM
for 29F-Cy3-52tr and 250 nM for 29F-Cy3-47tr. As a
control, cells were also treated with 29CMC, resulting in
dose-dependent inhibition of GFP expression, by up to
80% at 50 mM (Fig. 3d) (Stuyver et al., 2006). Although it
appeared that this compound was only effective at a much
higher concentration, it should be noted that the method
of delivery of the 29CMC was different to that of the
aptamers.
To confirm that the reduction in GFP expression correlated
with inhibition of replicon replication, 3Dpol expression
over time was investigated by immunoblotting. Fig. 4
Fig. 3. Quantification of pGFP-PAC replicon GFP expression over time in the presence and absence of aptamer. BHK-21 cells
were seeded and maintained for 24 h in 10% FCS/DMEM at 37 6C, 5% CO2 prior to transfection with 1 mg pGFP-PAC
replicon RNA. GFP expression was monitored using an IncuCyte FLR microscope. Data are presented as mean green object
count of the pGFP-PAC replicon over up to 12 h from the point at which GFP expression is first detected. (a) GFP expression
with 29F-Cy3-47tr, 29F-Cy3-52tr or cRNA at final concentrations of 500 nM. GFP expression with increasing concentrations (0
to 500 nM) of 29F-Cy3-47tr (b) or 29F-Cy3-52tr (c). (d) 29-CMC (0–50 mM). Shown is the mean object count from a collection
of nine images, allowing SE to be calculated.
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Fig. 4. Effect of aptamers on 3Dpol expression in BHK-21 cells
transfected with pGFP-PAC replicon. Cell extracts were prepared
at 4 h post-transfection. (a) Aliquots were analysed by SDS-PAGE
and immunoblotting for the presence of FMDV 3Dpol and cellular
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Cells
transfected with a D3Dpol replicon (pGFP-PAC-D3D), mock-
transfected or transfected with cRNA were included as controls.
(b) Densitometry was conducted using ImageJ imaging analysis
software on triplicate experiments for 3Dpol expression, normalized
to GAPDH. Data show mean values with SD (n53) and statistical
analysis performed using two-tailed paired t-test (*5P,0.05).
Inhibition of FMDV subgenomic replicon by RNA aptamers
http://vir.sgmjournals.org 2653
shows that 3Dpol could be detected at 4 h post-transfection
and that a band corresponding to the expected size of the
precursor protein 3CD was also evident. The 3Dpol and 3CD
bands were absent in the lane corresponding to the control
D3Dpol (a replicon including a deletion of most of the 3D
gene), as expected. In the presence of 29F-Cy3-47tr, the 3Dpol
level was greatly reduced (to 26.9±24.4 and 55.49±32.8%
with 500 and 250 nM, respectively, P,0.05). In addition,
there seemed to be a reduction in the 3CD translation
product with 29F-Cy3-47tr. Very little reduction was seen
with the cRNA (to 98.5±6.9 and 99.9±3.5% for 500 and
250 nM, respectively). The inhibition attributable to the
specific aptamer was therefore much more pronounced, and
appeared to be dose dependent.
Modified aptamers appear to be specific
inhibitors of replication
Previously, we showed that, in addition to sharing similarity
with each other, the aptamers also shared similarity with the
viral genome (Ellingham et al., 2006), particularly within the
59UTR. To ensure that the effects of the aptamers seen here
were related to replication and that the molecules were not
affecting translation by 39UTR or 59UTR binding, we
performed translation assays with bicistronic vectors. We
employed a construct with Renilla and firefly luciferase
reporter genes under cap- or FMDV IRES-mediated
translation, respectively (pRFMDVF) (Licursi et al., 2011).
The data in Fig. 5 show expression of both firefly and Renilla
luciferase from the pRFMDVF plasmid and showed that
levels were unaffected by 29F-Cy3-47tr, 29F-Cy3-52tr or the
cRNA (P.0.05). A construct (pRF) containing only a cap-
dependent reporter and cycloheximide (1 mg ml21) were
included as controls. For completeness, we also undertook
similar experiments with constructs incorporating other
viral IRES sequences (hepatitis C virus, human rhinovirus),
with similar results (data not shown).
DISCUSSION
Subgenomic replicons have proved useful tools in the study
of replication of a range of viruses, including hepatitis C
virus (Lohmann et al., 1999). Here, we use an FMDV
replicon to study replication in BHK-21 cells in the
presence of potential inhibitors. Protein expression (as
monitored by GFP reporter expression) acts as a direct
measure of replication (Tulloch et al., 2014). Continual
production of the RdRp 3Dpol facilitates replication of the
replicon RNA to provide increasing levels of template for
GFP expression, reaching maximal levels after approxi-
mately 8 h. This rapid expression of GFP is consistent with
the fast replication rate of FMDV and is mirrored by a
change in the morphology of the cells. It is likely that
expression of the Lpro is responsible for this cytotoxic effect
(Tulloch et al., 2014).
We have demonstrated that previously characterized RNA
aptamers selected against 3Dpol (the key enzyme in the
replication complex) can be modified to increase their
stability while maintaining effective inhibition of GFP
expression. This inhibition is dose dependent, with
maximal inhibition at 125–500 nM, which resulted in
restoration of normal cell morphology. The aptamers were
inhibitory at lower levels than seen with the control drug
29CMC. However, it should be noted that the method of
delivery of the drug and the aptamers (i.e. by transfection)
is different. Further studies are ongoing in order to
understand aptamer uptake and cellular localization.
It has beendocumented that chemically synthesized aptamers
are non-toxic and non-immunogenic. Themolecules used in
this study were small (31–33 nt). They are predicted to
possess minimal double-stranded regions (Doble et al., 2014;
Ellingham et al., 2006) and do not include a 59-triphosphate.
It is therefore unlikely that they will trigger RIG-I/MDA5 IFN
signalling (Belyaeva et al., 2014).We have shown that they are
well tolerated in cells and that the aptamers are able to reverse
the cytotoxic effects of replicon expression, with 29F-Cy3-
52tr being the most effective. The likely mode of action is via
direct inhibition of 3Dpol activity, thus preventing the
amplification of replication. There do not seem to be any
effects on translation, although other off-target effects cannot
be ruled out.
The first aptamer has been approved for clinical use (to
treat macular degeneration; Ng et al., 2006), and several
others are in clinical trials. Significantly, we have demon-
strated that it is possible to deliver small aptamer RNAs
passively to cells without the need for transfection reagents
(Doble et al., 2014), thus opening up possibilities for the
therapeutic use of aptamers in a topical/localized manner.
Furthermore, the inherent flexibility of RNA and con-
formational changes that occur upon target recognition
open up possible applications for aptamers in diagnostics,
alongside more conventional antibodies (reviewed by
Brody & Gold, 2000). Therefore, the RNA aptamers
described here, together with aptamers to other parts of
the replication complex, are useful molecular tools in the
study of replication but also have possible applications in
diagnostics and therapeutics in the future.
METHODS
Elongation assays. Recombinant 3Dpol (WT or D388A mutant) was
purified as described previously (Bentham et al., 2012). Elongation
assays were carried out using 2 mg poly(A) template (mean length
320) (Amersham), 2.4 mM oligo(dT)15 primer, 200 mMUTP, 5 mCi a-
[32P]UTP and 3Dpol to a final concentration of 1 mM in binding buffer
(30 mM MOPS, 10 mM NaCl, 25 mM magnesium acetate). For a
time-course experiment, 10 ml samples were taken at time points up
to 60 min and reactions stopped by addition of 10 ml 0.5 mM EDTA.
Samples were spotted onto separate DE-81 filter papers (Whatman)
and left to dry before washing five times with 200 ml 0.2 M
Na2HPO4, then with 500 ml dH2O for 1 min and finally 100 ml
100% ethanol for an additional minute. The filter papers were dried
before adding to scintillation fluid for quantification of a-[32P]UTP
incorporation by scintillation counting. For inhibition assays, 3Dpol
S. Forrest and others
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(1 mM) was pre-incubated with 4 mM aptamer RNA for 20 min
before addition to an elongation assay, as above.
Immunostaining of aptamer-transfected cells. BHK-21 cells were
employed as these are known to support vigorous FMDV replication.
Cells grown on coverslips in 12-well dishes and transfected with
50 nM aptamer were washed with PBS for 262 min before fixing
with ice-cold methanol for 10 min on ice. Cells were quickly washed
once with PBS and permeabilized with ice-cold 50% acetone/50%
methanol for 10 min and washed twice in PBS for 5 min. Coverslips
were removed from wells and mounted onto glass slides in
VectaShield plus DAPI (Vector Laboratories). Cells were imaged on
an upright confocal microscope (Zeiss).
pGFP-PAC replicon RNA transcription. A detailed description of
the pGFP-PAC replicon cloning strategy and characterization is
described elsewhere (Tulloch et al., 2014). A further construct
incorporating a deletion in 3Dpol was also described. To produce
template for transcription, 1 mg plasmid DNA was linearized using
1 U HpaI in final concentrations of 16 buffer 4 (NEB), 0.5 mg BSA in
a 20 ml reaction and incubated at 37 uC for at least 4 h. Products were
then analysed on a 1% agarose gel and linearized vector was excised
before gel purification. One microgram of linearized and purified
vector DNA was transcribed into RNA in a 20 ml reaction using T7
Megascript (Ambion) according to the manufacturer’s instructions.
Each reaction was carried out for 3 h at 37 uC before treating with
1 U TurboDNase for 15 min at 37 uC. Samples were then phenol/
(a)
50
40
30
20
10
60 Cap-dependent translation
IRES-mediated translation
0
pR
F
pRF
47
tr
52
tr
cR
NA
cy
clo 47
tr
52
tr
cR
NA
cy
clo
pR
FM
DV
pRFMDV
pR
F
pRF
47
tr
52
tr
cR
NA
cy
clo 47
tr
52
tr
cR
NA
cy
clo
pR
FM
DV
pFMDVF
10
–
4 
× 
Lu
ci
fe
ra
se
-f
or
m
in
g 
un
its
 (R
en
ill
a)
20
15
10
5
25
0
10
–
4 
× 
Lu
ci
fe
ra
se
-f
or
m
in
g 
un
its
 (f
ire
fly
)
(b)
Fig. 5. Effect of aptamers on translation. BHK-21 cells were transfected with a construct containing Renilla and firefly luciferase
reporter genes under either (a) cap- or (b) FMDV IRES-mediated translation respectively (pRFMDVF). At 24 h post-transfection
of the constructs, cells were subjected to a second transfection with aptamers 29F-Cy3-47tr, 29F-Cy3-52tr or cRNA. Cells
transfected with the pGFP-PAC replicon and either subjected to a second mock-transfection or treated with 1 mg
cycloheximide (cyclo) ml”1 were included as controls. Cells were lysed 24 h post-treatment and firefly and Renilla luciferase
units (RLU) were measured using the dual-luciferase reporter assay system (Promega). A construct (pRF) containing only a
cap-mediated Renilla luciferase reporter was included as a further control. Data are means±SE of three experiments. Statistical
analysis was conducted using a t-test (P,0.05).
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chloroform extracted and ethanol precipitated. After ethanol precipita-
tion, pellets were resuspended in 18 ml RNase-free water (Severn Biotech).
pGFP-PAC replicon RNA transfection. The following mixture was
prepared for each well of a 12-well plate: 1 mg pGFP-PAC replicon
RNA was added to 250 ml OptiMEM (Invitrogen) and incubated at
room temperature for 10–15 min. Complete Dulbecco’s modified
Eagle’s medium (DMEM) was removed from the BHK-21 cells and
replaced with the ESCORT reagent mixture (Sigma-Aldrich). The
cells were incubated at 37 uC in a humidified CO2 incubator for up to
14 h. As appropriate, aptamer RNA (up to 500 nM) was added to the
reaction pre-transfection. The control inhibitor, 29-C-methylcytidine
(29CMC), was prepared in 0.5% DMSO at a range of concentrations.
At 30 min post-transfection, cells were washed twice in PBS prior to
addition of 29CMC (final concentration 0–50 mM).
Immunoblotting. Cells were washed in PBS, lysed in lysis buffer (20 mM
Tris pH 7.5, 10% v/v glycerol, 1 mM EDTA, 150 mM NaCl, 1% v/v
Triton X-100) supplemented with Protease Inhibitor Cocktail (Roche)
and incubated on ice for 5 min before clarification. SDS-PAGEwas carried
out using a 10% gel system (Bio-Rad), followed by transfer of proteins to
PVDF membrane (Whatman). 3Dpol was detected with polyclonal rabbit
sera (kindly provided by Francisco Sobrino, Madrid) and secondary goat
anti-rabbit HRP conjugate (Pierce). Cellular glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), employed as an internal control protein, was
detected with an mAb (GAPDH-71.1, Sigma-Aldrich).
IncuCyte analysis of replication. GFP expression and live cell
imaging were analysed using IncuCyte FLR, an automated phase-
contrast and fluorescent microscope within a 37 uC humidifying CO2
incubator. After transfection and co-transfection of subgenomic
replicon RNA, cells were maintained in the IncuCyte and monitored
every 30 min for up to 12 h. At different time points, nine images of
each well were taken and GFP object count measurements analysed by
using the integrated algorithm.
RNA synthesis. Aptamers 29F-Cy3-47tr and 29F-Cy3-52tr
(Elllingham et al., 2006) and control cRNA were synthesized by
phosphoramidite chemistry in house. cRNA is a previously reported
aptamer selected to IL-17A, a non-viral protein (produced primarily
by CD4+ lymphocytes) (Doble et al., 2014).
The sequences of the aptamers used are as follows. Both 29F-Cy3-47tr
and 29F-Cy3-52tr include 29F C and cRNA includes 29F C and U: 29F-
Cy3-47tr, 59-Cy3-GGGUUAACAGAAAACCUCAGUUGCUGGGUU-
GU-39; 29F-Cy3-52tr, 59-Cy3-GGCUUACCCGUGAACCGCAGUUG-
CUGAGUUG-39; and cRNA, 59-GGUCUAGCCGGAGGAGUCAGU-
AAUCGGUAGACC-39.
Translation of bicistronic vectors. BHK-21 cells (16106) were
seeded in a 96-well plate culture plate and cultured overnight at 37 uC,
5% CO2. The cells in each well were transfected with 0.125 mg pRF or
pRFMDVF (Licursi et al., 2011) plasmid in the presence of 31.25 ml
OptiMEM and 0.625 ml ESCORT reagent. The plates were incubated
overnight at 37 uC and 5% CO2. At 24 h post-transfection, the cells were
transfected again with one of the following RNA aptamers at 500 nM –
29F-Cy3-47tr, 29F-Cy3-52tr or cRNA – or treated with cycloheximide
(Sigma) at 1 mg ml21. After incubation for a further 24 h, the cells were
lysed in 20 ml 16 Passive Lysis Buffer (Promega) and samples were
assayed using dual luciferase assay reagents using Stop and Glow substrate
in a 1 : 2 dilution according to themanufacturer’s instructions (Promega).
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